ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 52 filers reported holding ADC THERAPEUTICS SA in Q4 2020. The put-call ratio across all filers is 5.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $11,232,984 | +2263.3% | 3,554,742 | +570.8% | 0.00% | – |
| Q3 2023 | $475,311 | -52.8% | 529,890 | +13.1% | 0.00% | – |
| Q2 2023 | $1,007,286 | -18.7% | 468,505 | -26.3% | 0.00% | – |
| Q1 2023 | $1,239,316 | -38.7% | 635,547 | +20.6% | 0.00% | – |
| Q4 2022 | $2,022,877 | -1.9% | 526,791 | +23.1% | 0.00% | – |
| Q3 2022 | $2,063,000 | -44.4% | 427,866 | -8.3% | 0.00% | – |
| Q2 2022 | $3,711,000 | -17.0% | 466,804 | +53.4% | 0.00% | – |
| Q1 2022 | $4,469,000 | -24.7% | 304,229 | +3.5% | 0.00% | – |
| Q4 2021 | $5,936,000 | -30.3% | 293,857 | -6.3% | 0.00% | – |
| Q3 2021 | $8,518,000 | +16.3% | 313,641 | +4.3% | 0.00% | – |
| Q2 2021 | $7,323,000 | +38.6% | 300,738 | +82.2% | 0.00% | – |
| Q4 2020 | $5,283,000 | -3.0% | 165,021 | 0.0% | 0.00% | – |
| Q3 2020 | $5,444,000 | -29.3% | 165,021 | +0.3% | 0.00% | – |
| Q2 2020 | $7,700,000 | – | 164,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |